darifenacin

RN refers to (S),alpha,alpha-isomer; structure given in first source; Enablex transferred from Pfizer to Novartis 2003; muscarinic M(3) receptor antagonist that is indicated for use in treatment of overactive bladder disorder

Also Known As:

Networked: 79 relevant articles (10 outcomes, 22 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Wyndaele, Jean-Jacques: 4 articles (01/2012 - 09/2005)
2.	Ebinger, U: 4 articles (11/2008 - 10/2007)
3.	Rabasseda, X: 4 articles (04/2006 - 07/2004)
4.	Prous, J R: 4 articles (04/2006 - 07/2004)
5.	Foote, Jenelle: 3 articles (12/2011 - 03/2005)
6.	Steel, Michael: 3 articles (07/2008 - 11/2006)
7.	Hegde, Sharath S: 3 articles (01/2008 - 02/2006)
8.	Lheritier, Karine: 3 articles (11/2007 - 05/2006)
9.	Glavind, Karin: 3 articles (11/2006 - 05/2005)
10.	Kralidis, Georg: 3 articles (09/2005 - 03/2005)

Related Diseases

1.	Overactive Urinary Bladder (Overactive Bladder) 11/01/2006 - "To examine, in a 2-year, non-comparative, open-label extension study, the safety, tolerability and efficacy of darifenacin controlled-release (CR) 7.5/15 mg once daily in patients with overactive bladder (OAB) who completed two 12-week randomized, double-blind, placebo-controlled 'feeder' studies. " 05/01/2000 - "The results of ongoing clinical studies with darifenacin are awaited before it can be concluded that selective antagonism of M(3) receptors leads to improved tolerability over existing agents in the treatment of overactive bladder. " 04/01/2008 - "A comparison of the efficacy of darifenacin alone vs. darifenacin plus a Behavioural Modification Programme upon the symptoms of overactive bladder." 11/01/2007 - "This analysis evaluated the long-term safety, tolerability and efficacy of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder (OAB) in patients > or = 65 years of age. " 09/01/2007 - "These results may explain that the efficacy of darifenacin in overactive bladder symptoms is partly due to bladder afferent desensitization."
2.	Urinary Incontinence 01/01/2004 - "In multicentre, randomised, double-blind trials in patients with OAB, darifenacin 7.5 or 15 mg once daily for 12 weeks significantly reduced the frequency of urinary incontinence, frequency of micturition and frequency and severity of urgency versus placebo. " 10/01/2007 - "Mean urgency urinary incontinence episodes (UUIEs) decreased significantly from baseline to Week 12 with both darifenacin (-88.6%) and placebo (-77.9%; p > 0.05), with 70% and 58% patients responding with >or= 50% reductions, respectively (p = 0.021). " 01/01/2004 - "Darifenacin 15 mg once daily for 2 weeks was as effective as oxybutynin 5 mg three times daily at reducing the frequency of urinary incontinence and frequency and severity of urgency in patients with OAB. "
3.	Nocturia 05/01/2006 - "Darifenacin significantly reduced the median number of incontinence episodes/week (-68.7, -76.5, and -77.3% from baseline at 7.5, 15, and 30 mg, respectively, vs -46% with placebo, all p < 0.01) and dose relatedly improved micturition frequency, frequency and severity of urgency, nocturia, and bladder capacity. " 11/01/2004 - "Darifenacin is a novel M3 muscarinic selective receptor antagonist for once-daily treatment of overactive bladder (OAB), a highly prevalent, chronic and debilitating disease defined by urinary urgency with or without urge incontinence, usually with increased frequency of micturition and nocturia. "
4.	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 07/01/2010 - "The efficacy of darifenacin in diarrhea-predominant irritable bowel syndrome should be evaluated."
5.	Diarrhea 07/01/2010 - "The efficacy of darifenacin in diarrhea-predominant irritable bowel syndrome should be evaluated."

Related Drugs and Biologics

1.	tolterodine (Detrol)
2.	oxybutynin (Tavor)
3.	quinuclidin- 3'- yl- 1- phenyl- 1,2,3,4- tetrahydroisoquinoline- 2- carboxylate monosuccinate (solifenacin)
4.	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)
5.	Muscarinic Antagonists
6.	trospium chloride (Ceris)
7.	propiverine
8.	fesoterodine
9.	Atropine (Hyoscyamine)
10.	Pirenzepine

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Injections
3.	Drug Therapy (Chemotherapy)
4.	Castration